Does the media favor IDYA or BMRN?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat BioMarin Pharmaceutical's score of 0.64 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or MDGL?

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for Madrigal Pharmaceuticals. IDEAYA Biosciences' average media sentiment score of 0.85 beat Madrigal Pharmaceuticals' score of 0.41 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IDYA or HALO?

In the previous week, Halozyme Therapeutics had 15 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat Halozyme Therapeutics' score of 0.60 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat Arrowhead Pharmaceuticals' score of 0.14 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IDYA or KRYS?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.65 beat IDEAYA Biosciences' score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

IDEAYA Biosciences (IDYA) Competitors

$38.41 -0.20 (-0.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$37.86 -0.55 (-1.43%)

As of 09/18/2026 07:30 PM Eastern

Compare

IDYA vs. BMRN, MDGL, HALO, ARWR, and KRYS

Should you buy IDEAYA Biosciences stock or one of its competitors? IDEAYA Biosciences's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), and Krystal Biotech (KRYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

IDEAYA Biosciences (NASDAQ:IDYA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

IDEAYA Biosciences has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat BioMarin Pharmaceutical's score of 0.64 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a net margin of 2.14% compared to IDEAYA Biosciences' net margin of -75.93%. BioMarin Pharmaceutical's return on equity of 5.32% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

IDEAYA Biosciences presently has a consensus price target of $52.69, indicating a potential upside of 37.18%. BioMarin Pharmaceutical has a consensus price target of $89.17, indicating a potential upside of 39.46%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

BioMarin Pharmaceutical beats IDEAYA Biosciences on 13 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

IDEAYA Biosciences (NASDAQ:IDYA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

IDEAYA Biosciences presently has a consensus price target of $52.69, indicating a potential upside of 37.18%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 31.63%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for Madrigal Pharmaceuticals. IDEAYA Biosciences' average media sentiment score of 0.85 beat Madrigal Pharmaceuticals' score of 0.41 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A
Madrigal Pharmaceuticals	$958.40M	12.81	-$288.28M	-$12.89	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

IDEAYA Biosciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

IDEAYA Biosciences (NASDAQ:IDYA) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Halozyme Therapeutics has a net margin of 24.86% compared to IDEAYA Biosciences' net margin of -75.93%. Halozyme Therapeutics' return on equity of 260.98% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Halozyme Therapeutics	24.86%	260.98%	23.91%

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IDEAYA Biosciences has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

IDEAYA Biosciences currently has a consensus target price of $52.69, indicating a potential upside of 37.18%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 18.90%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe IDEAYA Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A
Halozyme Therapeutics	$1.66B	7.67	$316.89M	$3.35	33.57

In the previous week, Halozyme Therapeutics had 15 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat Halozyme Therapeutics' score of 0.60 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

IDEAYA Biosciences (NASDAQ:IDYA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IDEAYA Biosciences presently has a consensus target price of $52.69, suggesting a potential upside of 37.18%. Arrowhead Pharmaceuticals has a consensus target price of $99.15, suggesting a potential upside of 49.15%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEAYA Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A
Arrowhead Pharmaceuticals	$829.45M	11.29	-$1.63M	-$2.25	N/A

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.85 beat Arrowhead Pharmaceuticals' score of 0.14 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

IDEAYA Biosciences beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Krystal Biotech?

IDEAYA Biosciences (NASDAQ:IDYA) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Krystal Biotech has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A
Krystal Biotech	$389.13M	25.61	$204.83M	$7.98	42.19

Krystal Biotech has a net margin of 54.82% compared to IDEAYA Biosciences' net margin of -75.93%. Krystal Biotech's return on equity of 19.34% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Krystal Biotech	54.82%	19.34%	17.65%

IDEAYA Biosciences presently has a consensus price target of $52.69, indicating a potential upside of 37.18%. Krystal Biotech has a consensus price target of $365.40, indicating a potential upside of 8.53%. Given IDEAYA Biosciences' higher probable upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.65 beat IDEAYA Biosciences' score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

IDEAYA Biosciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Summary

Krystal Biotech beats IDEAYA Biosciences on 13 of the 17 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.39B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-19.80	14.08	273.81	25.39
Price / Sales	15.43	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	3.29	15.45	10.45	6.33
Net Income	-$113.70M	-$22.78M	$3.48B	$358.24M
7 Day Performance	2.18%	-1.22%	0.88%	1.17%
1 Month Performance	-1.18%	-4.44%	-1.59%	-2.59%
1 Year Performance	49.22%	37.78%	18.08%	5.97%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.1952 of 5 stars	$38.41 -0.5%	$52.69 +37.2%	+46.5%	$3.39B	$218.71M	N/A	145	High Trading Volume
BMRN BioMarin Pharmaceutical	4.6167 of 5 stars	$64.41 -0.3%	$89.17 +38.4%	+16.0%	$12.51B	$3.22B	174.08	3,221	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.0741 of 5 stars	$546.66 +2.3%	$699.64 +28.0%	+20.6%	$12.34B	$958.40M	N/A	90
HALO Halozyme Therapeutics	2.9481 of 5 stars	$107.39 -0.8%	$91.20 -15.1%	+46.6%	$12.29B	$1.66B	32.06	390	Trending News Insider Trade
ARWR Arrowhead Pharmaceuticals	2.809 of 5 stars	$82.63 -2.9%	$99.15 +20.0%	+111.0%	$11.99B	$829.45M	N/A	400	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. BMRN, MDGL, HALO, ARWR, and KRYS

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. BMRN, MDGL, HALO, ARWR, and KRYS

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Do insiders and institutionals believe in IDYA or BMRN?

Which has more risk and volatility, IDYA or BMRN?

Does the media favor IDYA or BMRN?

Is IDYA or BMRN more profitable?

Which has preferable earnings and valuation, IDYA or BMRN?

Do analysts rate IDYA or BMRN?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Do analysts rate IDYA or MDGL?

Does the media prefer IDYA or MDGL?

Which has higher valuation and earnings, IDYA or MDGL?

Is IDYA or MDGL more profitable?

Which has more volatility and risk, IDYA or MDGL?

Do insiders & institutionals have more ownership in IDYA or MDGL?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Is IDYA or HALO more profitable?

Do institutionals and insiders believe in IDYA or HALO?

Which has more risk & volatility, IDYA or HALO?

Do analysts recommend IDYA or HALO?

Which has preferable valuation & earnings, IDYA or HALO?

Does the media prefer IDYA or HALO?

Summary

How does IDEAYA Biosciences compare to Arrowhead Pharmaceuticals?

Is IDYA or ARWR more profitable?

Do institutionals & insiders hold more shares of IDYA or ARWR?

Do analysts rate IDYA or ARWR?

Which has more volatility and risk, IDYA or ARWR?

Which has higher valuation & earnings, IDYA or ARWR?

Does the media prefer IDYA or ARWR?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Which has preferable valuation & earnings, IDYA or KRYS?

Is IDYA or KRYS more profitable?

Do analysts recommend IDYA or KRYS?

Do institutionals and insiders believe in IDYA or KRYS?

Does the media prefer IDYA or KRYS?

Which has more volatility & risk, IDYA or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools